Safety and efficacy of S-1 plus oxaliplatin 130 mg/m 2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)
ConclusionsThis study represents the first evaluation of SOX130 in patients with HER2-negative AGC. SOX130 showed an acceptable safety profile, but the prespecified statistical efficacy targets were not achieved.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Anorexia | Brain | Cancer | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Neurology | Peripheral Neuropathy | Statistics | Study | Thrombocytopenia